Literature DB >> 28660302

Tumor angiogenesis and vascular normalization: alternative therapeutic targets.

Claire Viallard1, Bruno Larrivée2,3.   

Abstract

Tumor blood vessels are a key target for cancer therapeutic management. Tumor cells secrete high levels of pro-angiogenic factors which contribute to the creation of an abnormal vascular network characterized by disorganized, immature and permeable blood vessels, resulting in poorly perfused tumors. The hypoxic microenvironment created by impaired tumor perfusion can promote the selection of more invasive and aggressive tumor cells and can also impede the tumor-killing action of immune cells. Furthermore, abnormal tumor perfusion also reduces the diffusion of chemotherapeutic drugs and radiotherapy efficiency. To fight against this defective phenotype, the normalization of the tumor vasculature has emerged as a new therapeutic strategy. Vascular normalization, by restoring proper tumor perfusion and oxygenation, could limit tumor cell invasiveness and improve the effectiveness of anticancer treatments. In this review, we investigate the mechanisms involved in tumor angiogenesis and describe strategies used to achieve vascular normalization.

Entities:  

Keywords:  Angiogenesis; Improvement of cancer therapy; Maturation of blood vessels; Normalization; Tumor vasculature

Mesh:

Substances:

Year:  2017        PMID: 28660302     DOI: 10.1007/s10456-017-9562-9

Source DB:  PubMed          Journal:  Angiogenesis        ISSN: 0969-6970            Impact factor:   9.596


  314 in total

1.  Targeting the Tumor Core: Hypoxia-Responsive Nanoparticles for the Delivery of Chemotherapy to Pancreatic Tumors.

Authors:  Matthew I Confeld; Babak Mamnoon; Li Feng; Heather Jensen-Smith; Priyanka Ray; James Froberg; Jiha Kim; Michael A Hollingsworth; Mohiuddin Quadir; Yongki Choi; Sanku Mallik
Journal:  Mol Pharm       Date:  2020-07-22       Impact factor: 4.939

Review 2.  Advances in the role of exosomal non-coding RNA in the development, diagnosis, and treatment of gastric cancer (Review).

Authors:  Peng-Fei Gao; Da Huang; Jun-Yan Wen; Wei Liu; Hong-Wu Zhang
Journal:  Mol Clin Oncol       Date:  2020-06-10

3.  Cancer Explant Models.

Authors:  Christian T Stackhouse; George Yancey Gillespie; Christopher D Willey
Journal:  Curr Top Microbiol Immunol       Date:  2021       Impact factor: 4.291

Review 4.  Consensus guidelines for the use and interpretation of angiogenesis assays.

Authors:  Patrycja Nowak-Sliwinska; Kari Alitalo; Elizabeth Allen; Andrey Anisimov; Alfred C Aplin; Robert Auerbach; Hellmut G Augustin; David O Bates; Judy R van Beijnum; R Hugh F Bender; Gabriele Bergers; Andreas Bikfalvi; Joyce Bischoff; Barbara C Böck; Peter C Brooks; Federico Bussolino; Bertan Cakir; Peter Carmeliet; Daniel Castranova; Anca M Cimpean; Ondine Cleaver; George Coukos; George E Davis; Michele De Palma; Anna Dimberg; Ruud P M Dings; Valentin Djonov; Andrew C Dudley; Neil P Dufton; Sarah-Maria Fendt; Napoleone Ferrara; Marcus Fruttiger; Dai Fukumura; Bart Ghesquière; Yan Gong; Robert J Griffin; Adrian L Harris; Christopher C W Hughes; Nan W Hultgren; M Luisa Iruela-Arispe; Melita Irving; Rakesh K Jain; Raghu Kalluri; Joanna Kalucka; Robert S Kerbel; Jan Kitajewski; Ingeborg Klaassen; Hynda K Kleinmann; Pieter Koolwijk; Elisabeth Kuczynski; Brenda R Kwak; Koen Marien; Juan M Melero-Martin; Lance L Munn; Roberto F Nicosia; Agnes Noel; Jussi Nurro; Anna-Karin Olsson; Tatiana V Petrova; Kristian Pietras; Roberto Pili; Jeffrey W Pollard; Mark J Post; Paul H A Quax; Gabriel A Rabinovich; Marius Raica; Anna M Randi; Domenico Ribatti; Curzio Ruegg; Reinier O Schlingemann; Stefan Schulte-Merker; Lois E H Smith; Jonathan W Song; Steven A Stacker; Jimmy Stalin; Amber N Stratman; Maureen Van de Velde; Victor W M van Hinsbergh; Peter B Vermeulen; Johannes Waltenberger; Brant M Weinstein; Hong Xin; Bahar Yetkin-Arik; Seppo Yla-Herttuala; Mervin C Yoder; Arjan W Griffioen
Journal:  Angiogenesis       Date:  2018-08       Impact factor: 9.596

5.  Anti-angiogenesis therapy overcomes the innate resistance to PD-1/PD-L1 blockade in VEGFA-overexpressed mouse tumor models.

Authors:  Qiaohong Wang; Jingze Gao; Wen Di; Xia Wu
Journal:  Cancer Immunol Immunother       Date:  2020-04-28       Impact factor: 6.968

Review 6.  Improving cancer immunotherapy using nanomedicines: progress, opportunities and challenges.

Authors:  John D Martin; Horacio Cabral; Triantafyllos Stylianopoulos; Rakesh K Jain
Journal:  Nat Rev Clin Oncol       Date:  2020-02-07       Impact factor: 66.675

7.  Identification and validation of a 21-mRNA prognostic signature in diffuse lower-grade gliomas.

Authors:  Lai-Rong Song; Jian-Cong Weng; Xu-Lei Huo; Liang Wang; Huan Li; Da Li; Zhen Wu; Jun-Ting Zhang
Journal:  J Neurooncol       Date:  2019-12-18       Impact factor: 4.130

Review 8.  Anlotinib as a molecular targeted therapy for tumors.

Authors:  Yi Gao; Pengfei Liu; Ruihua Shi
Journal:  Oncol Lett       Date:  2020-05-28       Impact factor: 2.967

Review 9.  Anticancer Effects of Constituents of Herbs Targeting Osteosarcoma.

Authors:  Qing-Hong Su; Xiao-Qun Xu; Jun-Fu Wang; Jun-Wen Luan; Xia Ren; Hai-Yan Huang; Si-Shan Bian
Journal:  Chin J Integr Med       Date:  2019-06-04       Impact factor: 1.978

10.  Expression and Characterization of Human Vascular Endothelial Growth Factor Produced in SiHa Cells Transduced with Adenoviral Vector.

Authors:  N C Parra; R Mansilla; G Aedo; N S Vispo; E E González-Horta; I González-Chavarría; C Castillo; F Camacho; O Sánchez
Journal:  Protein J       Date:  2019-12       Impact factor: 2.371

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.